TRANSLATE

The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

lupus logo
Brought to you by Scientific Education Support

The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders. 

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Validation of childhood lupus low disease activity state definition

By Haimanti Mandal

Share:

Apr 9, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in systemic lupus erythematosus.

Childhood-onset systemic lupus erythematosus (cSLE) has a more severe disease course compared to adult-onset SLE.1 The Lupus Low Disease Activity State (LLDAS) seems to be realistic treat-to-target approach in these patients.1 An international taskforce developed an adapted LLDAS for cSLE called childhood Lupus Low Disease Activity State (cLLDAS) due to an unmet need for a cSLE-specific definition in this population.2 

Bergkamp et al.1 recently published an article in Clinical Immunology presenting the first study to validate the new cLLDAS definition in a real-life cohort of cSLE patients.1 Here, we summarize the key findings.

 

Methods1 

  • The new cLLDAS definition was retrospectively applied to prospectively collected data from the longitudinal, real-life cSLE cohort. 

  • The objectives of the study were to: 

    • compare the time to achieve first adult LLDAS (aLLDAS) vs cLLDAS; 

    • Assess if patients with cSLE could maintain cLLDAS for ≥50% of follow-up time (cLLDAS-50); and 

    • assess the predictors for cLLDAS-50 and occurrence of damage using univariate logistic regression analysis. 

Key findings1 

  • A total of 50 patients with cSLE were included; 86% were females and mean age at diagnosis was 14 years. 

cLLDAS 

  • Each patient attained aLLDAS and cLLDAS at least once during their follow-up. 

  • Mean time to attain first aLLDAS and cLLDAS was 8.2 and 9.0 months, respectively. 

    • However, this difference was only due to one patient. 

  • In 22 of the 42 patients, the mean delay to achieve first cLLDAS due to steroid dosage was 6.2 months. 

  • Median time spent in first cLLDAS was 3 months, with 78% patients not remaining in first cLLDAS. 

cLLDAS-50 

  • cLLDAS-50 was maintained in 58% of patients. 

  • The predictors for attaining cLLDAS-50, as per univariate analysis, are depicted in Figure 1A. 

    • In the multivariate analysis, a longer time from diagnosis to first cLLDAS (Odds ratio [OR], 0.828; p = 0.030) and higher number of flares (OR, 0.305; p = 0.04) were negative predictors for attaining cLLDAS-50. 

Damage 

  • Damage occurred in 34% of patients with a median follow-up of 3.1 years from diagnosis, with 64.7% experiencing damage within ≤1 year after diagnosis. 

  • The predictors of damage, as per univariate analysis, are depicted in Figure 1B.  

    • The significance of these predictors for damage disappeared in the multivariate model. 

Figure 1. Univariate logistic regression analysis of variables associated with A attainment of cLLDAS-50 and B occurrence of damage*  

CI, confidence interval; cLLDAS, childhood lupus low disease activity state; OR, odds ratio; PGA, physician global assessment; SLEDAI, Systemic Lupus Erythematosus Activity Index-2 K. 
*Data from Bergkamp, et al.1 


Key learnings
  • Time to reach cLLDAS differs from time to reach aLLDAS in cSLE, which validates the new cLLDAS definition.
  • Achieving cLLDAS is a feasible treatment goal in cSLE; however, attaining cLLDAS-50 appears challenging.
  • Biologics (if available) should be initiated earlier, especially in patients with cSLE with an African/Afro-Caribbean ethnic background, higher SLEDAI at diagnosis, and those who exhibit damage within first year after diagnosis.
  • Further treat-to-target trials are needed in patients with cSLE to gather more evidence on early steroid-tapering and initiating steroid-sparing drugs for preventing damage in cSLE.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

Systemic lupus erythematosus

Newsletter

Subscribe to get the best content delivered to your inbox